Trial Information

Efficacy of Postoperative Adjuvant Treatments After Hepatectomy and Thrombectomy for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third major
cause of cancer-related death. HCC is characterized by its propensity for portal vein
invasion. Portal vein tumor thrombosis (PVTT) can be detected macroscopically in the portal
vein in 44% to 62.2% of autopsy cases. The natural history of untreated HCC with PVTT is
dismal. The median survival of such patients was reported to be 2.7 mouths.

Non-surgical therapies, such as systemic/regional chemotherapy and transcatheter arterial
embolization / transcatheter arterial chemoembolization (TAE/TACE), are not effective in
treating HCC with PVTT. With the improvement of surgical techniques, surgical resection has
been reported to achieve promising results. However, the high rate of recurrence and
metastasis constitutes one of the most important challenges in improving surgical efficacy
for HCC with PVTT.

There is rare report about prevention and treatment of postoperative recurrence and
metastasis for HCC with macroscopical PVTT patients. We previously found the postoperative
portal vein infusion chemotherapy (PVIC) and TACE benefited PVTT patients, which required
further prospective randomized controlled studies with large case number to support our
findings. The randomized controlled trial was design to investigate the efficacy of the
different adjuvant chemotherapy strategies after hepatectomy and thrombectomy for HCC and
PVTT.